09:18 AM EDT, 03/27/2026 (MT Newswires) -- Health care stocks were declining premarket Friday, with the State Street Health Care Select Sector SPDR ETF ( XLV ) down 0.2% and the iShares Biotechnology ETF (IBB) 0.6% lower.

AstraZeneca ( AZN ) shares were up more than 3% after the company said its drug tozorakimab met its primary endpoint in two phase 3 trials in patients with chronic obstructive pulmonary disease.

Zenas BioPharma ( ZBIO ) stock was down more than 14% after the company priced a $200 million offering of 2.50% convertible senior notes due 2032 and a separate equity offering of 5 million shares at $20 per share.

ADMA Biologics ( ADMA ) shares were up more than 21% after the company refuted allegations in a March 24 report by Culper Research. ADMA Biologics ( ADMA ) said demand for its ASCENIV product "is real and growing," citing data provided by the company's distribution partners and direct customers.